EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Essential Thrombocythemia

Ayalew Tefferi, Naseema Gangat, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Natasha Szuber, Animesh Pardanani, Attilio Orazi, Tiziano Barbui, Alessandro Maria Vannucchi

JAMA · 25.02.2025 · 333 (8) · 701

DOI: 10.1001/jama.2024.25349 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 25.02.2025. Verfasst von Ayalew Tefferi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Hemorrhage, Thrombocythemia, Essential, Thrombosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Essential thrombocythemia, a clonal myeloproliferative neoplasm with excessive platelet production, is associated with an increased risk of thrombosis and bleeding. The annual incidence rate of essential thrombocythemia in the US is 1.5/100 000 persons. Observations Patients with essential thrombocythemia have a persistent platelet count of 450 × 10 9 /L or greater. The differential diagnosis includes myeloproliferative neoplasms (polycythemia vera, primary myelofibrosis, chronic myeloid leukemia); inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus; infections; splenectomy; iron deficiency anemia; and solid tumors such as lung cancer. Approximately 90% of individuals with essential thrombocythemia have genetic variants that upregulate the JAK-STAT (signal transducer and activator of transcription 5) signaling pathway, including Janus kinase 2 (JAK2, 64%), calreticulin (CALR , 23%), and myeloproliferative leukemia virus oncogene (MPL , 4%). The median age at diagnosis of essential thrombocythemia is 59 years. The median overall survival exceeds 35 years in those diagnosed at 40 years or younger. Patients with essential thrombocythemia are at increased risk of arterial thrombosis (11%), venous thrombosis (7%), and hemorrhagic complications (8%). Thrombosis risk is increased among those with a history of thrombosis, age older than 60 years, a JAK2 gene variant, and cardiovascular risk factors (eg, hypertension, diabetes mellitus, hyperlipidemias, tobacco use). Use of aspirin (81-100 mg/d) is suggested for most patients with essential thrombocythemia to lower thrombosis risk. In a retrospective study of 300 affected patients with a low thrombosis risk (younger than 60 years with no prior thrombosis), those not taking aspirin (100 mg/d) had a risk of arterial thrombosis of 9.4/1000 patient-years and a venous thrombosis risk of 8.2/1000 patient years; cardiovascular risk factors were associated with a higher risk of arterial thrombi (incidence rate ratio, 2.5 [95% CI, 1.02-6.1]), and a JAK2 gene variant was associated with increased risk of venous thrombosis (incidence rate ratio, 4.0 [95% CI, 1.2-12.9]). In a randomized trial of 114 patients at higher risk for thrombosis (age older than 60 years or a prior thrombotic event), cytoreduction with hydroxyurea significantly lowered the risk of arterial or venous thrombotic events compared with no cytoreductive therapy (3.6% vs 24%; P < .01). At a median of 8.5 years from diagnosis, approximately 10% of patients with essential thrombocythemia develop myelofibrosis and about 3% develop acute myeloid leukemia. Conclusions Essential thrombocythemia is a rare clonal myeloproliferative neoplasm associated with an increased risk of venous and arterial thrombosis, hemorrhage, myelofibrosis, and acute myeloid leukemia. Based on individual risk factors for thrombosis, persons with essential thrombocythemia may be treated with low-dose aspirin, either alone or in combination with a cytoreductive drug such as hydroxyurea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageThrombocythemia, EssentialThrombosisHumansAspirinJanus Kinase 2Platelet Aggregation InhibitorsRisk FactorsPlatelet CountDiagnosis, DifferentialSignal TransductionSTAT Transcription FactorsHydroxyureaPrimary MyelofibrosisLeukemia, Myeloid, AcuteDrug Therapy, Combination

Substanzen

AspirinJAK2 protein, humanJanus Kinase 2Platelet Aggregation InhibitorsSTAT Transcription FactorsHydroxyurea

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
  • Division of Hematology, University of Montreal, Montreal, Quebec, Canada.
  • Texas Tech University Health Sciences Center, El Paso.
  • Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Zitieren

APA

Tefferi, A., Gangat, N., Loscocco, G. G., Guglielmelli, P., Szuber, N., Pardanani, A., Orazi, A., Barbui, T., & Vannucchi, A. M. (2025). Essential Thrombocythemia. JAMA, 333(8), 701. https://doi.org/10.1001/jama.2024.25349

Vancouver

Tefferi A, Gangat N, Loscocco GG, Guglielmelli P, Szuber N, Pardanani A, et al. Essential Thrombocythemia. JAMA. 2025;333(8):701. doi:10.1001/jama.2024.25349

BibTeX
@article{Tefferi2025,
  author = {Tefferi, Ayalew and Gangat, Naseema and Loscocco, Giuseppe Gaetano and Guglielmelli, Paola and Szuber, Natasha and Pardanani, Animesh and Orazi, Attilio and Barbui, Tiziano and Vannucchi, Alessandro Maria},
  title = {Essential Thrombocythemia},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {8},
  pages = {701},
  doi = {10.1001/jama.2024.25349}
}
Kostenlos starten →